JP2020023549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020023549A5 JP2020023549A5 JP2019191044A JP2019191044A JP2020023549A5 JP 2020023549 A5 JP2020023549 A5 JP 2020023549A5 JP 2019191044 A JP2019191044 A JP 2019191044A JP 2019191044 A JP2019191044 A JP 2019191044A JP 2020023549 A5 JP2020023549 A5 JP 2020023549A5
- Authority
- JP
- Japan
- Prior art keywords
- naca
- therapeutic
- prophylactic agent
- agent according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2R)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 230000001225 therapeutic Effects 0.000 claims 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 claims 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- 201000004569 blindness Diseases 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 229960001305 Cysteine Hydrochloride Drugs 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- 229940067606 Lecithin Drugs 0.000 claims 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 1
- 229940075579 Propyl Gallate Drugs 0.000 claims 1
- 208000007014 Retinitis Pigmentosa Diseases 0.000 claims 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims 1
- 229960001295 Tocopherol Drugs 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N [(1R)-1-carboxy-2-sulfanylethyl]azanium;chloride;hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 claims 1
- 229960001563 acetylcysteine amide Drugs 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000008185 minitablet Substances 0.000 claims 1
- 230000004297 night vision Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229930003799 tocopherols Natural products 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Claims (10)
- N−アセチルシステインアミド(NACA)を含み、1回当たり、治療有効量のN−アセチルシステインアミド(NACA)の固体用量で100、150、300、333、400、500、600、700、750、800、900、1000、2500、5000、7500又は10000mgが投与される、ほ乳類における網膜色素変性症の治療剤又は予防剤。
- NACAが、薬学的に許容される担体中、又は薬学的に許容される担体と共に提供される、請求項1に記載の治療剤又は予防剤。
- NACAが、眼内、網膜下、硝子体内、経口、筋肉内、経皮、皮下、腹腔内、経腸、又は舌下に投与される、請求項1又は2に記載の治療剤又は予防剤。
- NACAが、ミニ錠剤、カプセル、錠剤、発泡剤、2段階放出、混合放出、サシェ、粉末、又は液剤を介して経口的に送達される、請求項3に記載の治療剤又は予防剤。
- NACAが、1日用量0.5〜150mg/Kgで投与される、請求項1〜4のいずれかに記載の治療剤又は予防剤。
- NACAが、夜間視力の欠損、全体的な視力の欠損、視野の欠損のうちの少なくとも1つを、2週間、1カ月、2カ月、3カ月、6カ月、1年、2年、又は5年のうちの少なくとも1つから選択される規定された期間にわたり、未治療の対照対象と比較して少なくとも10%、少なくとも15%、少なくとも20%、少なくとも25%、少なくとも30%、少なくとも35%、少なくとも40%、少なくとも45%、少なくとも50%、少なくとも55%、少なくとも60%、少なくとも65%、少なくとも70%、少なくとも75%、少なくとも80%、少なくとも85%、少なくとも90%、少なくとも95%、又はそれ以上減少させる治療有効量で投与される、請求項1〜4のいずれかに記載の治療剤又は予防剤。
- NACAが、1日2回又は3回投与される、請求項1〜6のいずれかに記載の治療剤又は予防剤。
- NACAが、第2の活性薬剤と共に投与される、請求項1〜7のいずれかに記載の治療剤又は予防剤。
- NACAが、アスコルビン酸、システイン塩酸塩、硫酸水素ナトリウム、メタ重亜硫酸ナトリウム、亜硫酸ナトリウム、パルミチン酸アスコルビル、ブチル化ヒドロキシアニソール(BHA)、ブチル化ヒドロキシトルエン(BHT)、レシチン、没食子酸プロピル、α−トコフェロール、クエン酸、エチレンジアミン四酢酸(EDTA)、ソルビトール、酒石酸、又はリン酸のうちの少なくとも1つから選択される第2の活性薬剤と共に投与される、請求項8に記載の治療剤又は予防剤。
- ほ乳類がヒトである、請求項1〜9のいずれかに記載の治療剤又は予防剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021147283A JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | N−アセチルシステインアミドによる網膜色素変性症の治療 |
JP2023127716A JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | N-アセチルシステインアミドによる網膜色素変性症の治療 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462076594P | 2014-11-07 | 2014-11-07 | |
US62/076,594 | 2014-11-07 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017544552A Division JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | N−アセチルシステインアミドによる網膜色素変性症の治療 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021147283A Division JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | N−アセチルシステインアミドによる網膜色素変性症の治療 |
JP2023127716A Division JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | N-アセチルシステインアミドによる網膜色素変性症の治療 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020023549A JP2020023549A (ja) | 2020-02-13 |
JP2020023549A5 true JP2020023549A5 (ja) | 2020-08-06 |
Family
ID=55909913
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017544552A Pending JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | N−アセチルシステインアミドによる網膜色素変性症の治療 |
JP2019191044A Pending JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | N−アセチルシステインアミドによる網膜色素変性症の治療 |
JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | N−アセチルシステインアミドによる網膜色素変性症の治療 |
JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | N-アセチルシステインアミドによる網膜色素変性症の治療 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017544552A Pending JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | N−アセチルシステインアミドによる網膜色素変性症の治療 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | N−アセチルシステインアミドによる網膜色素変性症の治療 |
JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | N-アセチルシステインアミドによる網膜色素変性症の治療 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20180296503A1 (ja) |
EP (2) | EP3214934A4 (ja) |
JP (4) | JP2017533969A (ja) |
KR (3) | KR20170109527A (ja) |
CN (2) | CN108498495A (ja) |
AU (4) | AU2015342831B2 (ja) |
BR (1) | BR112017009584A2 (ja) |
CA (1) | CA2967327C (ja) |
HK (1) | HK1252822A1 (ja) |
RU (1) | RU2711913C2 (ja) |
WO (2) | WO2016073829A2 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10752593B2 (en) | 2018-12-28 | 2020-08-25 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
WO2016077467A1 (en) | 2014-11-11 | 2016-05-19 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
AU2018338103B2 (en) | 2017-09-20 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
US20190135741A1 (en) * | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
US20190151271A1 (en) * | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
CN112399857A (zh) * | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Prc2亚单位的抑制治疗眼失调 |
CN109096161B (zh) * | 2018-08-24 | 2020-10-27 | 武汉远大弘元股份有限公司 | 一种n-乙酰半胱氨酸的制备方法 |
US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
EP3908341A4 (en) * | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
EP4093389A4 (en) * | 2020-01-24 | 2024-02-21 | NaCuity Pharmaceuticals, Inc. | PRODRUG FOR THE TREATMENT OF DISEASES AND INJURIES OF OXIDATIVE STRESS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101232877A (zh) * | 2005-04-21 | 2008-07-30 | 格伦·A·戈尔茨坦 | 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺(nac酰胺) |
KR20080028357A (ko) * | 2005-04-21 | 2008-03-31 | 글렌 에이. 골드스타인 | 산화성 스트레스에 관련된 질병 및 증상 치료용n-아세틸시스테인 아미드(nac 아미드) |
WO2013163545A1 (en) * | 2012-04-26 | 2013-10-31 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
-
2015
- 2015-11-06 JP JP2017544552A patent/JP2017533969A/ja active Pending
- 2015-11-06 AU AU2015342831A patent/AU2015342831B2/en active Active
- 2015-11-06 RU RU2017119230A patent/RU2711913C2/ru active
- 2015-11-06 CN CN201810698779.7A patent/CN108498495A/zh active Pending
- 2015-11-06 BR BR112017009584A patent/BR112017009584A2/pt not_active Application Discontinuation
- 2015-11-06 WO PCT/US2015/059418 patent/WO2016073829A2/en active Application Filing
- 2015-11-06 US US15/524,636 patent/US20180296503A1/en not_active Abandoned
- 2015-11-06 CA CA2967327A patent/CA2967327C/en active Active
- 2015-11-06 WO PCT/US2015/059589 patent/WO2016073931A1/en active Application Filing
- 2015-11-06 US US15/523,665 patent/US20170333375A1/en active Pending
- 2015-11-06 EP EP15857309.7A patent/EP3214934A4/en not_active Ceased
- 2015-11-06 KR KR1020177015227A patent/KR20170109527A/ko active Application Filing
- 2015-11-06 CN CN201580072224.6A patent/CN107426997A/zh active Pending
- 2015-11-06 EP EP21217485.8A patent/EP4000612A1/en active Pending
- 2015-11-06 KR KR1020227009489A patent/KR20220039853A/ko active Application Filing
- 2015-11-06 KR KR1020237036499A patent/KR20230152177A/ko not_active Application Discontinuation
-
2018
- 2018-09-20 HK HK18112150.1A patent/HK1252822A1/zh unknown
-
2019
- 2019-10-18 JP JP2019191044A patent/JP2020023549A/ja active Pending
- 2019-11-07 AU AU2019261762A patent/AU2019261762B2/en active Active
-
2021
- 2021-09-06 AU AU2021225263A patent/AU2021225263B2/en active Active
- 2021-09-10 JP JP2021147283A patent/JP2021193119A/ja active Pending
-
2023
- 2023-08-04 JP JP2023127716A patent/JP2023145734A/ja active Pending
-
2024
- 2024-01-24 AU AU2024200436A patent/AU2024200436A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020023549A5 (ja) | ||
JP2017533969A5 (ja) | ||
CA2388609A1 (en) | Oxcarbazepine formulations for administration with or without food | |
WO2006102446A3 (en) | Multi-particulate, modified-released colonic composition | |
RU2010147287A (ru) | Комбинированная композиция | |
RU2017119230A (ru) | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом | |
HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
AR028299A1 (es) | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. | |
CO4940409A1 (es) | Tableta cubierta con pelicula para seguridad mejorada del tracto gastrointestinal superior | |
IT1271495B (it) | Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi | |
DE60020551D1 (de) | Orale formulierung zur verabreichung in den ileum enthaltend einen hemmstoff des ileum-gallensäuretransports | |
JP2010525050A5 (ja) | ||
TW200630123A (en) | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form | |
JP2008543936A5 (ja) | ||
WO2007038428A3 (en) | Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds | |
ECSP045409A (es) | Composiciones y metodos para dosificar liposomas de ciertos tamaños a fin de tratar o prevenir enfermedades. | |
BRPI0513598A (pt) | formas de dosagem em comprimidos revestidos de liberação entérica | |
UA85359C2 (ru) | Таблетка, содержащая гранулированный материал с kmd-3213 | |
CA2453263A1 (en) | Pharmaceutical compositions containing terbinafine and use thereof | |
CA2411882A1 (en) | Solid valsartan pharmaceutical compositions | |
RU2010106225A (ru) | Композиция и способ с использованием стабилизированного чувствительного ингредиента | |
JP2016505050A5 (ja) | ||
RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
JP2005525329A5 (ja) |